XFOR vs ABBV vs JPM vs BMY vs AMGN

For growth investors, X4 Pharmaceuticals, Inc.

(XFOR) is the stronger pick with 1273% revenue growth year-over-year, versus -0. 2% for Bristol-Myers Squibb Company (BMY). JPMorgan Chase & Co. (JPM) offers the better valuation at 16. 0x trailing P/E (14. 4x forward), making it the more compelling value choice. Analysts rate X4 Pharmaceuticals, Inc. (XFOR) a "Buy" — based on 13 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, JPMorgan Chase & Co.

(JPM) is the cheapest at 16. 0x versus AbbVie Inc. at 96. 1x. On forward P/E, Bristol-Myers Squibb Company is actually cheaper at 9. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: JPMorgan Chase & Co. wins at 0. 81x versus Amgen Inc. 's 5. 39x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, AbbVie Inc.

(ABBV) delivered a total return of +123. 7%, compared to -98. 4% for X4 Pharmaceuticals, Inc. (XFOR). Over 10 years, the gap is even starker: JPM returned +465. 8% versus XFOR's -99. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), AbbVie Inc.

(ABBV) is the lower-risk stock at 0. 14β versus X4 Pharmaceuticals, Inc. 's 2. 35β — meaning XFOR is approximately 1626% more volatile than ABBV relative to the S&P 500. On balance sheet safety, X4 Pharmaceuticals, Inc. (XFOR) carries a lower debt/equity ratio of 41% versus 6% for Amgen Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), X4 Pharmaceuticals, Inc.

(XFOR) is pulling ahead at 1273% versus -0. 2% for Bristol-Myers Squibb Company (BMY). On earnings-per-share growth, the picture is similar: Bristol-Myers Squibb Company grew EPS 178. 2% year-over-year, compared to -0. 8% for AbbVie Inc.. Over a 3-year CAGR, AMGN leads at 11. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Amgen Inc.

(AMGN) is the more profitable company, earning 21. 0% net margin versus -225. 6% for X4 Pharmaceuticals, Inc. — meaning it keeps 21. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ABBV leads at 32. 8% versus -247. 4% for XFOR. At the gross margin level — before operating expenses — XFOR leads at 82. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, JPMorgan Chase & Co. (JPM) is the more undervalued stock at a PEG of 0. 81x versus Amgen Inc. 's 5. 39x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Bristol-Myers Squibb Company (BMY) trades at 9. 0x forward P/E versus 16. 0x for AbbVie Inc. — 6. 9x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for XFOR: 200. 0% to $12. 00.

In this comparison, BMY (4.

3% yield), ABBV (2. 9% yield), AMGN (2. 7% yield), JPM (1. 9% yield) pay a dividend. XFOR does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 14), 2. 9% yield, +362. 2% 10Y return). X4 Pharmaceuticals, Inc. (XFOR) carries a higher beta of 2. 35 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (ABBV: +362. 2%, XFOR: -99. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (XFOR (Healthcare) and ABBV (Healthcare) and JPM (Financial Services) and BMY (Healthcare) and AMGN (Healthcare)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: XFOR is a small-cap high-growth stock; ABBV is a large-cap quality compounder stock; JPM is a large-cap deep-value stock; BMY is a mid-cap deep-value stock; AMGN is a mid-cap quality compounder stock. ABBV, JPM, BMY, AMGN pay a dividend while XFOR does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.